1. Home
  2. CNTX vs RMI Comparison

CNTX vs RMI Comparison

Compare CNTX & RMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNTX
  • RMI
  • Stock Information
  • Founded
  • CNTX 2015
  • RMI 2018
  • Country
  • CNTX United States
  • RMI United States
  • Employees
  • CNTX N/A
  • RMI N/A
  • Industry
  • CNTX Biotechnology: Pharmaceutical Preparations
  • RMI Finance/Investors Services
  • Sector
  • CNTX Health Care
  • RMI Finance
  • Exchange
  • CNTX Nasdaq
  • RMI Nasdaq
  • Market Cap
  • CNTX 75.6M
  • RMI 88.8M
  • IPO Year
  • CNTX 2021
  • RMI N/A
  • Fundamental
  • Price
  • CNTX $0.85
  • RMI $14.55
  • Analyst Decision
  • CNTX Strong Buy
  • RMI
  • Analyst Count
  • CNTX 5
  • RMI 0
  • Target Price
  • CNTX $5.25
  • RMI N/A
  • AVG Volume (30 Days)
  • CNTX 121.2K
  • RMI 17.4K
  • Earning Date
  • CNTX 11-05-2025
  • RMI 01-01-0001
  • Dividend Yield
  • CNTX N/A
  • RMI 7.28%
  • EPS Growth
  • CNTX N/A
  • RMI N/A
  • EPS
  • CNTX N/A
  • RMI N/A
  • Revenue
  • CNTX N/A
  • RMI N/A
  • Revenue This Year
  • CNTX N/A
  • RMI N/A
  • Revenue Next Year
  • CNTX N/A
  • RMI N/A
  • P/E Ratio
  • CNTX N/A
  • RMI N/A
  • Revenue Growth
  • CNTX N/A
  • RMI N/A
  • 52 Week Low
  • CNTX $0.49
  • RMI $13.05
  • 52 Week High
  • CNTX $2.59
  • RMI $17.37
  • Technical
  • Relative Strength Index (RSI)
  • CNTX 55.84
  • RMI 73.57
  • Support Level
  • CNTX $0.81
  • RMI $14.41
  • Resistance Level
  • CNTX $0.87
  • RMI $14.66
  • Average True Range (ATR)
  • CNTX 0.05
  • RMI 0.13
  • MACD
  • CNTX -0.01
  • RMI 0.08
  • Stochastic Oscillator
  • CNTX 39.79
  • RMI 86.93

About CNTX Context Therapeutics Inc.

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

About RMI RiverNorth Opportunistic Municipal Income Fund Inc.

RiverNorth Opportunistic Municipal Income Fund, Inc. is a diversified, closed-end management investment company. Its investment objective is to seek current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.

Share on Social Networks: